Monday’s Midday Stock Update: Karyopharm Therapeutics (KPTI), Peabody Energy Comm (BTU), Arrowhead Research (ARWR), Blueprint Medicines (BPMC), Aerie Pharma (AERI)

By Carrie Williams

So far Monday, December 2, NASDAQ is down -4.72% and the S&P is down -2.6%. Here are this morning’s most active stocks: Karyopharm Therapeutics (KPTIResearch Report), Peabody Energy Comm (BTUResearch Report), Arrowhead Research (ARWRResearch Report), Blueprint Medicines (BPMCResearch Report) and Aerie Pharma (AERIResearch Report).

Karyopharm Therapeutics is down -7.68% in midday trading to $17.08. Shares opened today at $18.50. The company has a 52-week low of $3.92 and a 52-week high of $18.70. On the Street’s front, the average 12-month analyst price target for the stock is $23.60, marking a 27.57% potential upside from current levels. In a report issued on November 6, Wedbush analyst David Nierengarten maintained a Buy rating on KPTI, with a price target of $18.00, which represents a slight downside potential from current levels.

Peabody Energy Comm is down -7.52% in midday trading to $9.01. Shares opened today at $9.74. The company has a 52-week low of $8.65 and a 52-week high of $35.11. On the Street’s front, the average 12-month analyst price target for the stock is $16.67, marking a 71.15% potential upside from current levels. In a report issued on October 30, B.Riley FBR analyst Lucas Pipes downgraded BTU to Hold, with a price target of $12.00, which implies an upside of 23% from current levels. Separately, on the same day, Deutsche Bank’s Chris Terry maintained a Buy rating on the stock and has a price target of $24.00.

Arrowhead Research is down -6.74% in midday trading to $68.39. Shares opened today at $73.33. The company has a 52-week low of $10.41 and a 52-week high of $73.72. On the Street’s front, the average 12-month analyst price target for the stock is $67.60, marking a -7.81% potential downside from current levels. In a report issued on November 29, Chardan analyst Keay Nakae reiterated a Buy rating on ARWR, with a price target of $81.00, which represents a potential upside of 10% from where the stock is currently trading. Separately, on November 19, Cantor Fitzgerald’s Elemer Piros maintained a Hold rating on the stock and has a price target of $50.00. In the last 30 days, insiders purchased $65.65K worth of ARWR shares. Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 43 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Blueprint Medicines is down -6.01% in midday trading to $76.55. Shares opened today at $81.45. The company has a 52-week low of $44.58 and a 52-week high of $102.98. On the Street’s front, the average 12-month analyst price target for the stock is $103.86, marking a 27.51% potential upside from current levels. In a report issued on November 7, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BPMC, with a price target of $100.00, which represents a potential upside of 23% from where the stock is currently trading. Separately, on October 28, Deutsche Bank’s Konstantinos Aprilakis downgraded the stock to Hold and has a price target of $75.00. Over the last 3 months, the insider sentiment on Blueprint Medicines has been positive based on 31 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Aerie Pharma is down -4.57% in midday trading to $18.39. Shares opened today at $19.27. The company has a 52-week low of $17.15 and a 52-week high of $50.10. On the Street’s front, the average 12-month analyst price target for the stock is $42.43, marking a 120.19% potential upside from current levels. In a report issued on November 29, Needham analyst Serge Belanger maintained a Buy rating on AERI, with a price target of $40.00, which implies an upside of 108% from current levels. In the last 30 days, insiders purchased $1.22M worth of AERI shares. Over the last 3 months, the insider sentiment on Aerie Pharma has been positive based on 44 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>